SAB Biotherapeutics announced Samuel Reich, currently the Executive Chairman of SAB, will expand his role to include that of CEO of SAB, effective February 2, 2024. Eddie Sullivan, Ph.D., Co-Founder of SAB, will continue his role as President, and as a member of the Board of Directors. He will report to the Board and maintain leadership of operational, research, and development functions of the Company. Reich joined SAB in 2021 as Executive Chairman of the Board of Directors after its combination with Big Cypress Acquisition Group, where he served as CEO, CFO and a member of the board of directors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SABS:
- SAB Biotherapeutics Inc trading resumes
- SAB Biotherapeutics Inc trading halted, volatility trading pause
- SAB Biotherapeutics Signs Sales Deal with Cantor Fitzgerald
- SAB Biotherapeutics Regains Compliance with Nasdaq Rules
- SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
